ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
111.38
+0.71 (+0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close110.67
Open110.61
Bid0.00 x 1000
Ask109.80 x 800
Day's Range110.50 - 111.43
52 Week Range34.53 - 114.20
Volume510,053
Avg. Volume2,015,293
Market Cap4.224B
Beta (3Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.97
Trade prices are not sourced from all markets
  • Roche faces further delay in $4.3 billion Spark deal amid FTC review
    Reuters3 hours ago

    Roche faces further delay in $4.3 billion Spark deal amid FTC review

    Roche on Friday announced another extension of its $4.3 billion (£3.3 billion) offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • Reuters3 hours ago

    Roche faces further delay in $4.3 bln Spark deal amid FTC review

    Roche on Friday announced another extension of its $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • Reuters4 hours ago

    Roche again extends $4.3 blillion offer for Spark amid FTC review

    Roche on Friday announced another extension of the Swiss drugmaker's $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • GlobeNewswire5 hours ago

    Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

    OTCQX: RHHBY) and Spark Therapeutics, Inc. (ONCE) ("Spark") today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the "HSR Act") in connection with Roche`s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the "Offer"). The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process.  In order to provide the government with additional time to complete its current review, Roche has elected to withdraw and refile the Premerger Notification and Report Form under the HSR Act.

  • Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
    Zacks8 days ago

    Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

    Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

  • GlobeNewswire9 days ago

    Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it will serve as the inaugural sponsor of Believe Limited’s first-ever science fair, which will be hosted at the National Hemophilia Foundation’s 71st Bleeding Disorders Conference, Oct. 3 – 5, 2019, in Anaheim, CA. The Science Fair™ will educate children and adults with hemophilia as well as other attendees about the science behind bleeding disorders in a number of engaging ways.

  • Reuters9 days ago

    Swiss drugmaker Roche ups outlook as sales growth offsets price hit

    By John Miller ZURICH (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald ...

  • GlobeNewswire11 days ago

    Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. – ONCE

    Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spark Therapeutics, Inc. (“Spark” or the “Company”) (ONCE) in connection with the proposed sale of Spark to Roche Holdings, Inc. (“Roche”). If you are a Spark shareholder and would like to discuss your legal rights and options, please visit Spark (ONCE) Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The lawsuit alleges that Defendants issued a materially misleading proxy statement recommending that Spark shareholders tender their shares to Roche.

  • Ophthotech Gets Rights to Gene Therapy for BEST Disease
    Zacks14 days ago

    Ophthotech Gets Rights to Gene Therapy for BEST Disease

    Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks15 days ago

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • ACCESSWIRE17 days ago

    COMPLAINTS FILED - ELLI and ONCE: Levi & Korsinsky, LLP Reminds Investors of Complaints Filed Concerning the Sale of these Companies

    NEW YORK, NY / ACCESSWIRE / April 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that complaints have been filed on behalf of shareholders of ...

  • 4 Gene Therapy Players Likely to Become Buyout Targets in 2019
    Zacks18 days ago

    4 Gene Therapy Players Likely to Become Buyout Targets in 2019

    Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

  • Health Day Checkup of Medical ETFs: 5 Top Picks
    Zacks21 days ago

    Health Day Checkup of Medical ETFs: 5 Top Picks

    M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

  • GlobeNewswire21 days ago

    Rigrodsky & Long, P.A. Files Class Action Suit Against Spark Therapeutics, Inc.

    WILMINGTON, Del., April 04, 2019 -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District.

  • Reuters23 days ago

    Deals of the day-Mergers and acquisitions

    ** Malaysia will sell a superyacht allegedly bought with stolen funds from state fund 1MDB to casino operator Genting Malaysia Bhd for $126 million, in the first major asset sale by Kuala Lumpur to recover billions lost from the fund. ** Saudi Arabia's AlRajhi Holding Group and Dubai's Al Ghurair have teamed up in a consortium to bid for Saudi Arabian state grain buyer SAGO's flour mills, three sources familiar with the matter told Reuters. ** Deutsche Bank and Commerzbank are divided over the pace of their merger talks, two people with knowledge of the matter said.

  • Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal
    American City Business Journals23 days ago

    Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal

    Roche received offers representing about 29 percent of Sparks’s outstanding shares before the deadline was extended.

  • Sangamo Rises on Positive Phase I/II Hemophilia Study Data
    Zacks23 days ago

    Sangamo Rises on Positive Phase I/II Hemophilia Study Data

    Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.

  • Roche Extends Offer Period for Spark Therapeutics Acquisition
    Zacks23 days ago

    Roche Extends Offer Period for Spark Therapeutics Acquisition

    Roche (RHHBY) withdraws its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics.

  • TheStreet.com23 days ago

    Roche Buys More Time in $4.3B Offer for Spark Therapeutics

    In a press release, the Swiss company confirmed on Wednesday it will be extending its offer to May 2 from the original deadline of Wednesday, April 3, after receiving support for its takeover deal from less than 30% of Spark shareholders. Roche also said a review of the acquisition by the U.S. Federal Trade Commission, the government agency which seeks to prevent anti-competitive practices, was taking more time than anticipated and its plans had had to be refiled. "All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.

  • Benzinga23 days ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • Roche says $4.3 billion Spark offer still on track for June completion
    Reuters23 days ago

    Roche says $4.3 billion Spark offer still on track for June completion

    Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it. A spokesman said Roche remained confident the deal would be completed by the end of June. "All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.

  • Reuters23 days ago

    European shares climb for fourth day on trade optimism, China data

    European shares rose for the fourth straight session on Wednesday, as investors took heart from further signs of recovery in China and progress towards a possible trade deal between Beijing and Washington. White House economic adviser Larry Kudlow said on Tuesday he expects the United States and China "to make more headway" as the two sides resume trade talks this week. Strong economic data out of China has also helped sentiment.

  • Most Analysts Have Given bluebird bio Positive Ratings in March
    Market Realist28 days ago

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing